The second clinical case presents a patient with ROS1 fusion-positive advanced NSCLC who achieved partial response on ...
SAN DIEGO, April 16, 2020 (GLOBE NEWSWIRE) -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results